MedTrace Logo

Cardiopulmonary Bypass Induced Red Blood Cell Lysis

NCT05189262 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-08-19

No results posted yet for this study

Summary

Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.

Conditions

  • Cardiopulmonary Bypass
  • Cardiac Surgery
  • Kidney Injury, Acute

Interventions

OTHER

Blood and urine collection

No intervention - Biological specimen collection

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Paul Buehler, PhD · University of Maryland

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-22
Primary Completion
2027-12-31
Completion
2027-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05189262 on ClinicalTrials.gov